STRATTEC SECURITY CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that STRATTEC SECURITY CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jul 1, 2018 | $439.20M | Sep 6, 2018 |
| FY2018 | Jul 2, 2017 | $417.33M | Sep 6, 2018 |
| FY2018 | Jul 3, 2016 | $401.42M | Sep 6, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $565.07M | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | $537.77M | Aug 25, 2025 |
| FY2024 | Jul 2, 2023 | $492.95M | Sep 5, 2024 |
| FY2023 | Jul 3, 2022 | $452.27M | Sep 7, 2023 |
| FY2022 | Jun 27, 2021 | $485.30M | Sep 8, 2022 |
| FY2020 | Jun 28, 2020 | $42.12M | Sep 3, 2020 |
| FY2020 | Mar 29, 2020 | $116.94M | Sep 3, 2020 |
| FY2020 | Dec 29, 2019 | $106.28M | Sep 3, 2020 |
| FY2020 | Sep 29, 2019 | $119.96M | Sep 3, 2020 |
| FY2020 | Jun 30, 2019 | $128.70M | Sep 3, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $84.58M | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | $65.47M | Aug 25, 2025 |
| FY2024 | Jul 2, 2023 | $42.15M | Sep 5, 2024 |
| FY2023 | Jul 3, 2022 | $56.02M | Sep 7, 2023 |
| FY2022 | Jun 27, 2021 | $78.66M | Sep 8, 2022 |
| FY2020 | Jun 28, 2020 | ($7.78M) | Sep 3, 2020 |
| FY2020 | Mar 29, 2020 | $17.01M | Sep 3, 2020 |
| FY2020 | Dec 29, 2019 | $10.33M | Sep 3, 2020 |
| FY2020 | Sep 29, 2019 | $15.89M | Sep 3, 2020 |
| FY2020 | Jun 30, 2019 | $14.20M | Sep 3, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $18.69M | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | $16.31M | Aug 25, 2025 |
| FY2024 | Jul 2, 2023 | ($6.67M) | Sep 5, 2024 |
| FY2023 | Jul 3, 2022 | $7.02M | Sep 7, 2023 |
| FY2022 | Jun 27, 2021 | $22.53M | Sep 8, 2022 |
| FY2020 | Jun 28, 2020 | ($10.50M) | Sep 3, 2020 |
| FY2020 | Mar 29, 2020 | $2.99M | Sep 3, 2020 |
| FY2020 | Dec 29, 2019 | ($1.34M) | Sep 3, 2020 |
| FY2020 | Sep 29, 2019 | $1.24M | Sep 3, 2020 |
| FY2020 | Jun 30, 2019 | ($62.0K) | Sep 3, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $22.78M | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | $17.81M | Aug 25, 2025 |
| FY2024 | Jul 2, 2023 | ($6.09M) | Sep 5, 2024 |
| FY2023 | Jul 3, 2022 | $8.90M | Sep 7, 2023 |
| FY2022 | Jun 27, 2021 | $33.92M | Sep 8, 2022 |
| FY2021 | Jun 28, 2020 | ($8.66M) | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $10.61M | Sep 3, 2020 |
| FY2019 | Jul 1, 2018 | $13.28M | Sep 5, 2019 |
| FY2018 | Jul 2, 2017 | $14.84M | Sep 6, 2018 |
| FY2018 | Jul 3, 2016 | $22.18M | Sep 6, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $21.70M | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | $14.80M | Aug 25, 2025 |
| FY2024 | Jul 2, 2023 | $15.90M | Sep 5, 2024 |
| FY2023 | Jul 3, 2022 | $12.20M | Sep 7, 2023 |
| FY2022 | Jun 27, 2021 | $10.80M | Sep 8, 2022 |
| FY2021 | Jun 28, 2020 | $9.80M | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $13.80M | Sep 3, 2020 |
| FY2019 | Jul 1, 2018 | $4.80M | Sep 5, 2019 |
| FY2018 | Jul 2, 2017 | $4.60M | Sep 6, 2018 |
| FY2018 | Jul 3, 2016 | $430.0K | Sep 6, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $71.68M | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | $12.27M | Aug 25, 2025 |
| FY2024 | Jul 2, 2023 | $10.10M | Sep 5, 2024 |
| FY2023 | Jul 3, 2022 | $10.44M | Sep 7, 2023 |
| FY2022 | Jun 27, 2021 | $35.15M | Sep 8, 2022 |
| FY2021 | Jun 28, 2020 | $25.42M | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $29.94M | Sep 3, 2020 |
| FY2019 | Jul 1, 2018 | $6.94M | Sep 5, 2019 |
| FY2018 | Jul 2, 2017 | $23.14M | Sep 6, 2018 |
| FY2018 | Jul 3, 2016 | $8.22M | Sep 6, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $7.16M | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | $9.79M | Aug 25, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $391.45M | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | $364.29M | Aug 25, 2025 |
| FY2024 | Jul 2, 2023 | $340.93M | Sep 5, 2024 |
| FY2023 | Jul 3, 2022 | $319.13M | Sep 7, 2023 |
| FY2022 | Jun 27, 2021 | $310.56M | Sep 8, 2022 |
| FY2021 | Jun 28, 2020 | $265.55M | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $312.74M | Sep 3, 2020 |
| FY2019 | Jul 1, 2018 | $307.18M | Sep 5, 2019 |
| FY2018 | Jul 2, 2017 | $273.71M | Sep 6, 2018 |
| FY2017 | Jul 3, 2016 | $242.18M | Sep 7, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $145.02M | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | $138.67M | Aug 25, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $221.59M | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | $200.55M | Aug 25, 2025 |
| FY2024 | Jul 2, 2023 | $184.96M | Sep 5, 2024 |
| FY2023 | Jul 3, 2022 | $188.40M | Sep 7, 2023 |
| FY2023 | Jun 27, 2021 | $181.01M | Sep 7, 2023 |
| FY2021 | Jun 28, 2020 | $152.22M | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $163.39M | Sep 3, 2020 |
| FY2019 | Jul 1, 2018 | $162.16M | Sep 5, 2019 |
| FY2018 | Jul 2, 2017 | $151.09M | Sep 6, 2018 |
| FY2017 | Jul 3, 2016 | $139.33M | Sep 7, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $269.30M | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | $250.61M | Aug 25, 2025 |
| FY2024 | Jul 2, 2023 | $234.30M | Sep 5, 2024 |
| FY2023 | Jul 3, 2022 | $240.97M | Sep 7, 2023 |
| FY2023 | Jun 27, 2021 | $233.95M | Sep 7, 2023 |
| FY2021 | Jun 28, 2020 | $211.94M | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $221.12M | Sep 3, 2020 |
| FY2019 | Jul 1, 2018 | $236.16M | Sep 5, 2019 |
| FY2018 | Jul 2, 2017 | $225.91M | Sep 6, 2018 |
| FY2017 | Jul 3, 2016 | $220.73M | Sep 7, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $84.58M | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | $25.41M | Aug 25, 2025 |
| FY2024 | Jul 2, 2023 | $20.57M | Sep 5, 2024 |
| FY2023 | Jul 3, 2022 | $8.77M | Sep 7, 2023 |
| FY2022 | Jun 27, 2021 | $14.47M | Sep 8, 2022 |
| FY2021 | Jun 28, 2020 | $11.77M | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $7.81M | Sep 3, 2020 |
| FY2019 | Jul 1, 2018 | $8.09M | Sep 5, 2019 |
| FY2018 | Jul 2, 2017 | $8.36M | Sep 6, 2018 |
| FY2018 | Jul 3, 2016 | $15.48M | Sep 6, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | 4 | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | 4 | Aug 25, 2025 |
| FY2024 | Jul 2, 2023 | (1) | Sep 5, 2024 |
| FY2023 | Jul 3, 2022 | 1 | Sep 7, 2023 |
| FY2022 | Jun 27, 2021 | 5 | Sep 8, 2022 |
| FY2020 | Jun 28, 2020 | (2) | Sep 3, 2020 |
| FY2020 | Mar 29, 2020 | 0 | Sep 3, 2020 |
| FY2020 | Dec 29, 2019 | 0 | Sep 3, 2020 |
| FY2020 | Sep 29, 2019 | 0 | Sep 3, 2020 |
| FY2020 | Jun 30, 2019 | 0 | Sep 3, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | 4 | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | 4 | Aug 25, 2025 |
| FY2024 | Jul 2, 2023 | (1) | Sep 5, 2024 |
| FY2023 | Jul 3, 2022 | 1 | Sep 7, 2023 |
| FY2022 | Jun 27, 2021 | 5 | Sep 8, 2022 |
| FY2020 | Jun 28, 2020 | (2) | Sep 3, 2020 |
| FY2020 | Mar 29, 2020 | 0 | Sep 3, 2020 |
| FY2020 | Dec 29, 2019 | 0 | Sep 3, 2020 |
| FY2020 | Sep 29, 2019 | 0 | Sep 3, 2020 |
| FY2020 | Jun 30, 2019 | 0 | Sep 3, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | 4.04M | Aug 25, 2025 |
| FY2025 | Jun 30, 2024 | 3.99M | Aug 25, 2025 |
| FY2025 | Jul 2, 2023 | 3.93M | Aug 25, 2025 |
| FY2023 | Jul 3, 2022 | 3.88M | Sep 7, 2023 |
| FY2022 | Jun 27, 2021 | 3.81M | Sep 8, 2022 |
| FY2021 | Jun 28, 2020 | 3.75M | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | 3.69M | Sep 3, 2020 |
| FY2019 | Jul 1, 2018 | 3.64M | Sep 5, 2019 |
| FY2018 | Jul 2, 2017 | 3.60M | Sep 6, 2018 |
| FY2017 | Jul 3, 2016 | 3.57M | Sep 7, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Jun 28, 2020 | $1.57M | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $2.06M | Sep 3, 2020 |
| FY2019 | Jul 1, 2018 | $2.03M | Sep 5, 2019 |
| FY2018 | Jul 2, 2017 | $2.01M | Sep 6, 2018 |
| FY2018 | Jul 3, 2016 | $1.87M | Sep 6, 2018 |
| FY2017 | Jun 28, 2015 | $1.71M | Sep 7, 2017 |
| FY2016 | Jun 29, 2014 | $1.54M | Sep 8, 2016 |
| FY2015 | Jun 30, 2013 | $1.35M | Sep 4, 2015 |
| FY2014 | Jul 1, 2012 | $1.34M | Sep 5, 2014 |
| FY2013 | Jul 3, 2011 | $3.99M | Sep 9, 2013 |